1
|
Paulis LE, Schnerr RS, Halton J, Qin ZZ, Chua A. Assessment of scattered and leakage radiation from ultra-portable X-ray systems in chest imaging: An independent study. PLOS GLOBAL PUBLIC HEALTH 2025; 5:e0003986. [PMID: 39854582 PMCID: PMC11761074 DOI: 10.1371/journal.pgph.0003986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Accepted: 11/07/2024] [Indexed: 01/26/2025]
Abstract
Ultraportable (UP) X-ray devices are ideal to use in community-based settings, particularly for chest X-ray (CXR) screening of tuberculosis (TB). Unfortunately, there is insufficient guidance on the radiation safety of these devices. This study aims to determine the radiation dose by UP X-ray devices to both the public and radiographers compared to international dose limits. Radiation dose measurements were performed with four UP X-ray devices that met international criteria, utilizing a clinically representative CXR set-up made with a thorax phantom. Scatter and leakage radiation dose were measured at various positions surrounding the phantom and X-ray tube, respectively. These measurements were used to calculate yearly radiation doses for different scenarios based on the median of all UP X-ray devices. From the yearly scatter doses, the minimum distances from the phantom needed to stay below the international public dose limit (1 mSv/year) were calculated. This distance was longest in the direction back towards the X-ray tube and shortest to the left/right sides of the phantom, e.g., 4.5 m and 2.5 m resp. when performing 50 exams/day, at 90 kV, 2.5 mAs and source skin distance (SSD) 1 m. Additional calculations including leakage radiation were conducted at a typical radiographer position (i.e., behind the X-ray tube), with a correction factor for wearing a lead apron. At 2 m behind the X-ray tube, a radiographer wearing a lead apron could perform 106 exams/day at 2.5 mAs and 29 exams/day at 10 mAs (90 kV, SSD 1 m), while keeping his/her radiation dose below the public dose limit (1 mSv/year) and well below the radiographer dose limit (20 mSv/year). In most CXR screening scenarios, the radiation dose of UP X-ray devices can be kept below 1 mSv/year by employing basic radiation safety rules on time, distance and shielding and using appropriate CXR exposure parameters.
Collapse
Affiliation(s)
- Leonie E. Paulis
- Médecins Sans Frontières, International, Amsterdam, The Netherlands
- Department of Digital Health, Stop TB, Geneva, Switzerland
- Department of Medical Physics, Maxima Medical Center, Veldhoven, The Netherlands
| | - Roald S. Schnerr
- Médecins Sans Frontières, International, Amsterdam, The Netherlands
- Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Jarred Halton
- Médecins Sans Frontières, International, Amsterdam, The Netherlands
| | - Zhi Zhen Qin
- Department of Digital Health, Stop TB, Geneva, Switzerland
| | - Arlene Chua
- Médecins Sans Frontières, International, Geneva, Switzerland
| |
Collapse
|
2
|
Officer K, Webster N, Rosenblatt AJ, Sorphea P, Warren K, Jackson B. Comparative thoracic radiography in healthy and tuberculosis-positive sun bears ( Helarctos malayanus). Front Vet Sci 2025; 11:1460140. [PMID: 39834926 PMCID: PMC11743561 DOI: 10.3389/fvets.2024.1460140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2024] [Accepted: 12/10/2024] [Indexed: 01/22/2025] Open
Abstract
Early and accurate diagnosis of pulmonary tuberculosis (TB) is key to effective outbreak management, and in humans thoracic radiography is used extensively for screening purposes. In wildlife TB radiography is a relatively accessible diagnostic tool, particularly in under-resourced settings, however its use is limited by body size. Sun bears are susceptible to human-associated TB, and their small body size makes thoracic radiography feasible. However, there are no established guidelines on normal thoracic radiographs or radiographic manifestations of TB in this species. We provide a first description of thoracic radiographs from healthy and TB affected sun bears at a bear rescue sanctuary, including correlation with postmortem results for a subset of bears. Findings of two veterinary radiologists, blinded to clinical information, revealed high agreement on broad categorization of radiographic studies as normal, abnormal, or needing correlation with further information. Agreement was lower for the presence of specific lung patterns, reflecting inherent subjectivity when classifying these features. Very few studies were identified as definitively normal, however definitively abnormal studies were significantly associated with TB cases. Diffuse bronchial and/or bronchointerstitital lung patterns were commonly reported, with a high proportion needing correlation with age and/or clinical signs to further interpret. Interstitial, interstitial-to-alveolar, alveolar and nodular lung patterns, along with radiographic signs of lymphadenomegaly and pleural fluid, were almost exclusively found in TB cases, however the sensitivity of the presence of any of these changes for detecting TB was below 70%. Radiographic reporting of thoracic lymph node enlargement detected at postmortem was low (4/17; 23%), and aortic outflow tract dilation and positional atelectasis were differential diagnoses for radiographic changes that could also represent TB. Together these findings demonstrate the importance of developing species-specific criteria for interpretation, to differentiate between common findings and manifestations of TB, and to highlight areas where radiographic techniques can be optimized to assist this. Given TB remains a global health challenge in humans and other animals (wild or domestic), and detection is key to control, we recommend development of standardized approaches to radiographic studies and their interpretation to bolster diagnostic pathways for detecting TB in sun bears, and other novel or understudied hosts.
Collapse
Affiliation(s)
- Kirsty Officer
- School of Veterinary Medicine, Murdoch University, Perth, WA, Australia
- Free the Bears, Phnom Penh, Cambodia
| | - Natalie Webster
- Diagnostic Imaging Department, Melbourne Animal Specialist Hospital, Melbourne, VIC, Australia
| | - Alana J. Rosenblatt
- School of Veterinary Science, The University of Queensland, Gatton, QLD, Australia
| | | | - Kris Warren
- School of Veterinary Medicine, Murdoch University, Perth, WA, Australia
- Centre for Terrestrial Ecosystem Science and Sustainability, Harry Butler Institute, Murdoch University, Perth, WA, Australia
| | - Bethany Jackson
- School of Veterinary Medicine, Murdoch University, Perth, WA, Australia
- Centre for Biosecurity and One Health, Harry Butler Institute, Murdoch University, Perth, WA, Australia
| |
Collapse
|
3
|
Meiyanti M, Bachtiar A, Kusumaratna RK, Alfiyyah A, Machrumnizar M, Pusparini P. Tuberculosis treatment outcomes and associated factors: A retrospective study in West Nusa Tenggara, Indonesia. NARRA J 2024; 4:e1660. [PMID: 39816109 PMCID: PMC11731667 DOI: 10.52225/narra.v4i3.1660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2024] [Accepted: 12/13/2024] [Indexed: 01/05/2025]
Abstract
Successfully treating tuberculosis (TB) could significantly help reduce its spread. The aim of this study was to identify factors associated with successful TB treatment. A retrospective study was conducted in West Nusa Tenggara, Indonesia, using data from the National TB Information System (SITB) covering patients from January 1 to December 31, 2022. Patients were classified into two groups: those with successful treatment outcomes (cured or completed treatment) and those with unsuccessful outcomes (including treatment failure, loss to follow-up, or death). Univariate and multivariate logistic regression analyses were performed to identify factors associated with treatment outcomes, providing odds ratios (OR) and adjusted odds ratios (aOR) with 95% confidence intervals (CIs). A total of 2,225 TB patients (1,382 males and 843 females) were included in the study. Of these, 2,048 (92.1%) achieved successful treatment outcomes. Univariate analysis indicated that older age (OR: 0.47; 95%CI: 0.28-0.78) and a high number of AFB in sputum smears (OR: 0.23; 95%CI: 0.09-0.66) were associated with a higher likelihood of unsuccessful TB treatment. In contrast, having no HIV infection (OR: 13.44; 95%CI: 6.22-29.08), clinical TB cases (diagnosed clinically rather than bacteriologically) (OR: 1.50; 95%CI: 1.04-2.20) and longer duration of TB treatments were associated with successful treatment outcomes. Multivariate analysis suggested that the TB treatment durations of 4-6 months (aOR: 1256.95; 95%CI: 431.89-3658.19) and 7-12 months (aOR: 575.5; 95%CI: 99.1-3342.06) were associated with a significantly higher likelihood of success compared to durations of 0-3 months. In conclusion, this study highlights that a minimum treatment duration of three months was crucial for increasing the likelihood of successful TB treatment. These findings emphasize the importance of comprehensive support programs to ensure adherence to treatment guidelines and improve outcomes.
Collapse
Affiliation(s)
- Meiyanti Meiyanti
- Philosophy Doctor in Public Health Program, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia
- Department of Pharmacology and Pharmacy, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia
| | - Adang Bachtiar
- Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia
| | - Rina K. Kusumaratna
- Department of Public Health, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia
| | - Arifah Alfiyyah
- Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia
| | | | - Pusparini Pusparini
- Department of Clinical Pathology, Faculty of Medicine, Universitas Trisakti, Jakarta, Indonesia
| |
Collapse
|
4
|
Davis NM, El-Said E, Fortune P, Shen A, Succi MD. Transforming Health Care Landscapes: The Lever of Radiology Research and Innovation on Emerging Markets Poised for Aggressive Growth. J Am Coll Radiol 2024; 21:1552-1556. [PMID: 39096946 DOI: 10.1016/j.jacr.2024.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2024] [Accepted: 07/30/2024] [Indexed: 08/05/2024]
Abstract
Advances in radiology are crucial not only to the future of the field but to medicine as a whole. Here, we present three emerging areas of medicine that are poised to change how health care is delivered-hospital at home, artificial intelligence, and precision medicine-and illustrate how advances in radiological tools and technologies are helping to fuel the growth of these markets in the United States and across the globe.
Collapse
Affiliation(s)
- Nicole M Davis
- Innovation Office, Mass General Brigham, Somerville, Massachusetts
| | - Ezat El-Said
- Medically Engineered Solutions in Healthcare Incubator, Innovations in Operations Research Center, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
| | - Patrick Fortune
- Vice President, Strategic Innovation Leaders at Mass General Brigham, Innovation Office, Mass General Brigham, Somerville, Massachusetts
| | - Angela Shen
- Innovation Office, Mass General Brigham, Somerville, Massachusetts; Vice President, Strategic Innovation Leaders at Mass General Brigham
| | - Marc D Succi
- Innovation Office, Mass General Brigham, Somerville, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Medically Engineered Solutions in Healthcare Incubator, Innovations in Operations Research Center, Massachusetts General Hospital, Boston, Massachusetts. MDS is the Associate Chair of Innovation and Commercialization at Mass General Brigham Enterprise Radiology; Strategic Innovation Leader at Mass General Brigham Innovation; Founder and Executive Director of the MESH Incubator at Mass General Brigham.
| |
Collapse
|
5
|
Codlin AJ, Vo LNQ, Garg T, Banu S, Ahmed S, John S, Abdulkarim S, Muyoyeta M, Sanjase N, Wingfield T, Iem V, Squire B, Creswell J. Expanding molecular diagnostic coverage for tuberculosis by combining computer-aided chest radiography and sputum specimen pooling: a modeling study from four high-burden countries. BMC GLOBAL AND PUBLIC HEALTH 2024; 2:52. [PMID: 39100507 PMCID: PMC11291606 DOI: 10.1186/s44263-024-00081-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Accepted: 07/05/2024] [Indexed: 08/06/2024]
Abstract
Background In 2022, fewer than half of persons with tuberculosis (TB) had access to molecular diagnostic tests for TB due to their high costs. Studies have found that the use of artificial intelligence (AI) software for chest X-ray (CXR) interpretation and sputum specimen pooling can each reduce the cost of testing. We modeled the combination of both strategies to estimate potential savings in consumables that could be used to expand access to molecular diagnostics. Methods We obtained Xpert testing and positivity data segmented into deciles by AI probability scores for TB from the community- and healthcare facility-based active case finding conducted in Bangladesh, Nigeria, Viet Nam, and Zambia. AI scores in the model were based on CAD4TB version 7 (Zambia) and qXR (all other countries). We modeled four ordinal screening and testing approaches involving AI-aided CXR interpretation to indicate individual and pooled testing. Setting a false negative rate of 5%, for each approach we calculated additional and cumulative savings over the baseline of universal Xpert testing, as well as the theoretical expansion in diagnostic coverage. Results In each country, the optimal screening and testing approach was to use AI to rule out testing in deciles with low AI scores and to guide pooled vs individual testing in persons with moderate and high AI scores, respectively. This approach yielded cumulative savings in Xpert tests over baseline ranging from 50.8% in Zambia to 57.5% in Nigeria and 61.5% in Bangladesh and Viet Nam. Using these savings, diagnostic coverage theoretically could be expanded by 34% to 160% across the different approaches and countries. Conclusions Using AI software data generated during CXR interpretation to inform a differentiated pooled testing strategy may optimize TB diagnostic test use, and could extend molecular tests to more people who need them. The optimal AI thresholds and pooled testing strategy varied across countries, which suggests that bespoke screening and testing approaches may be needed for differing populations and settings. Supplementary Information The online version contains supplementary material available at 10.1186/s44263-024-00081-2.
Collapse
Affiliation(s)
- Andrew James Codlin
- Friends for International TB Relief, Hanoi, Viet Nam
- Karolinska Institutet, Stockholm, Sweden
| | - Luan Nguyen Quang Vo
- Friends for International TB Relief, Hanoi, Viet Nam
- Karolinska Institutet, Stockholm, Sweden
| | | | | | | | | | | | - Monde Muyoyeta
- Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
| | - Nsala Sanjase
- Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
| | - Tom Wingfield
- Karolinska Institutet, Stockholm, Sweden
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom
- Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
| | - Vibol Iem
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Bertie Squire
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | | |
Collapse
|
6
|
Shah AP, Dave JD, Makwana MN, Rupani MP, Shah IA. A mixed-methods study on impact of active case finding on pulmonary tuberculosis treatment outcomes in India. Arch Public Health 2024; 82:92. [PMID: 38902803 PMCID: PMC11188491 DOI: 10.1186/s13690-024-01326-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Accepted: 06/15/2024] [Indexed: 06/22/2024] Open
Abstract
BACKGROUND Tuberculosis (TB) remains a significant public health burden in India, with elimination targets set for 2025. Active case finding (ACF) is crucial for improving TB case detection rates, although conclusive evidence of its association with treatment outcomes is lacking. Our study aims to investigate the impact of ACF on successful TB treatment outcomes among pulmonary TB patients in Gujarat, India, and explore why ACF positively impacts these outcomes. METHODS We conducted a retrospective cohort analysis in Gujarat, India, including 1,638 pulmonary TB cases identified through ACF and 80,957 cases through passive case finding (PCF) from January 2019 to December 2020. Generalized logistic mixed-model compared treatment outcomes between the ACF and PCF groups. Additionally, in-depth interviews were conducted with 11 TB program functionaries to explore their perceptions of ACF and its impact on TB treatment outcomes. RESULTS Our analysis revealed that patients diagnosed through ACF exhibited 1.4 times higher odds of successful treatment outcomes compared to those identified through PCF. Program functionaries emphasized that ACF enhances case detection rates and enables early detection and prompt treatment initiation. This early intervention facilitates faster sputum conversion and helps reduce the infectious period, thereby improving treatment outcomes. Functionaries highlighted that ACF identifies TB cases that might otherwise be missed, ensuring timely and appropriate treatment. CONCLUSION ACF significantly improves TB treatment outcomes in Gujarat, India. The mixed-methods analysis demonstrates a positive association between ACF and successful TB treatment, with early detection and prompt treatment initiation being key factors. Insights from TB program functionaries underscore the importance of ACF in ensuring timely diagnosis and treatment, which are critical for better treatment outcomes. Expanding ACF initiatives, especially among hard-to-reach populations, can further enhance TB control efforts. Future research should focus on optimizing ACF strategies and integrating additional interventions to sustain and improve TB treatment outcomes.
Collapse
Affiliation(s)
- Akshat P Shah
- Department of Community Medicine, Government Medical College Bhavnagar (Maharaja Krishnakumarsinhji Bhavnagar University), Near ST Bus Stand, Jail Road, Bhavnagar, Gujarat, 364001, India
| | - Jigna D Dave
- Department of Respiratory Medicine, Government Medical College Bhavnagar (Maharaja Krishnakumarsinhji Bhavnagar University), Jail Road, Bhavnagar, Gujarat, 364001, India
| | - Mohit N Makwana
- Department of Community Medicine, Government Medical College Bhavnagar (Maharaja Krishnakumarsinhji Bhavnagar University), Near ST Bus Stand, Jail Road, Bhavnagar, Gujarat, 364001, India
- Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Khanderi, Parapipaliya, Rajkot, Gujarat, 360006, India
| | - Mihir P Rupani
- Department of Community Medicine, Government Medical College Bhavnagar (Maharaja Krishnakumarsinhji Bhavnagar University), Near ST Bus Stand, Jail Road, Bhavnagar, Gujarat, 364001, India.
- Clinical Epidemiology (Division of Health Sciences), ICMR - National Institute of Occupational Health (NIOH), Indian Council of Medical Research (ICMR), Meghaninagar, Near Raksha Shakti University, Ahmedabad, Gujarat, 380016, India.
| | - Immad A Shah
- Division of Agricultural Statistics, Sher-e-Kashmir University of Agricultural Sciences & Technology of Kashmir, Jammu & Kashmir, Srinagar, 190025, India
| |
Collapse
|
7
|
Worodria W, Castro R, Kik SV, Dalay V, Derendinger B, Festo C, Nguyen TQ, Raberahona M, Sudarsan S, Andama A, Thangakunam B, Lyimo I, Nguyen VN, Rakotoarivelo R, Theron G, Yu C, Denkinger CM, Lapierre SG, Cattamanchi A, Christopher DJ, Jaganath D. An independent, multi-country head-to-head accuracy comparison of automated chest x-ray algorithms for the triage of pulmonary tuberculosis. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2024:2024.06.19.24309061. [PMID: 38946949 PMCID: PMC11213091 DOI: 10.1101/2024.06.19.24309061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/02/2024]
Abstract
Background Computer-aided detection (CAD) algorithms for automated chest X-ray (CXR) reading have been endorsed by the World Health Organization for tuberculosis (TB) triage, but independent, multi-country assessment and comparison of current products are needed to guide implementation. Methods We conducted a head-to-head evaluation of five CAD algorithms for TB triage across seven countries. We included CXRs from adults who presented to outpatient facilities with at least two weeks of cough in India, Madagascar, the Philippines, South Africa, Tanzania, Uganda, and Vietnam. The participants completed a standard evaluation for pulmonary TB, including sputum collection for Xpert MTB/RIF Ultra and culture. Against a microbiological reference standard, we calculated and compared the accuracy overall, by country and key groups for five CAD algorithms: CAD4TB (Delft Imaging), INSIGHT CXR (Lunit), DrAid (Vinbrain), Genki (Deeptek), and qXR (qure.AI). We determined the area under the ROC curve (AUC) and if any CAD product could achieve the minimum target accuracy for a TB triage test (≥90% sensitivity and ≥70% specificity). We then applied country- and population-specific thresholds and recalculated accuracy to assess any improvement in performance. Results Of 3,927 individuals included, the median age was 41 years (IQR 29-54), 12.9% were people living with HIV (PLWH), 8.2% living with diabetes, and 21.2% had a prior history of TB. The overall AUC ranged from 0.774-0.819, and specificity ranged from 64.8-73.8% at 90% sensitivity. CAD4TB had the highest overall accuracy (73.8% specific, 95% CI 72.2-75.4, at 90% sensitivity), although qXR and INSIGHT CXR also achieved the target 70% specificity. There was heterogeneity in accuracy by country, and females and PLWH had lower sensitivity while males and people with a history of TB had lower specificity. The performance remained stable regardless of diabetes status. When country- and population-specific thresholds were applied, at least one CAD product could achieve or approach the target accuracy for each country and sub-group, except for PLWH and those with a history of TB. Conclusions Multiple CAD algorithms can achieve or exceed the minimum target accuracy for a TB triage test, with improvement when using setting- or population-specific thresholds. Further efforts are needed to integrate CAD into routine TB case detection programs in high-burden communities.
Collapse
Affiliation(s)
- William Worodria
- 1. World Alliance for Lung and Intensive Care in Uganda, Kampala, Uganda
| | - Robert Castro
- 2. Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, USA
- 3. Center for Tuberculosis, University of California, San Francisco, USA
| | | | - Victoria Dalay
- 5. De La Salle Medical and Health Sciences Institute, Dasmarinas Cavite, Philippines
| | - Brigitta Derendinger
- 6. DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa
| | - Charles Festo
- 7. Ifakara Health Institute, Dar es Salaam, Tanzania
| | - Thanh Quoc Nguyen
- 8. Vietnam National Tuberculosis Programme, National Lung Hospital, Hanoi, Vietnam
- 9. VNU University of Medicine and Pharmacy, Hanoi, Vietnam
| | - Mihaja Raberahona
- 10. Department of Infectious Diseases, CHU Joseph Raseta Befelatanana, Antananarivo, Madagascar
- 11. Centre d’Infectiologie Charles Mérieux, Université d’Antananarivo, Antananarivo, Madagascar
| | - Swati Sudarsan
- 2. Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, USA
- 3. Center for Tuberculosis, University of California, San Francisco, USA
| | - Alfred Andama
- 1. World Alliance for Lung and Intensive Care in Uganda, Kampala, Uganda
| | - Balamugesh Thangakunam
- 12. Department of Pulmonary Medicine, Christian Medical College, Vellore, Tamil Nadu, India
| | - Issa Lyimo
- 7. Ifakara Health Institute, Dar es Salaam, Tanzania
| | - Viet Nhung Nguyen
- 8. Vietnam National Tuberculosis Programme, National Lung Hospital, Hanoi, Vietnam
- 9. VNU University of Medicine and Pharmacy, Hanoi, Vietnam
| | - Rivo Rakotoarivelo
- 11. Centre d’Infectiologie Charles Mérieux, Université d’Antananarivo, Antananarivo, Madagascar
- 13. Faculté de Médecine, Université de Fianarantsoa, Fianarantsoa, Madagascar
| | - Grant Theron
- 6. DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa
| | - Charles Yu
- 5. De La Salle Medical and Health Sciences Institute, Dasmarinas Cavite, Philippines
| | - Claudia M. Denkinger
- 14. Department of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
- 15. German Center for Infection Research, partner site, Heidelberg, Germany
| | - Simon Grandjean Lapierre
- 16. Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Immunopathology Axis, Montréal, Canada
- 17. Université de Montréal, Department of Microbiology, Infectious Diseases and Immunology, Montréal, Canada
| | - Adithya Cattamanchi
- 3. Center for Tuberculosis, University of California, San Francisco, USA
- 18. Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of California Irvine, Orange, USA
| | | | - Devan Jaganath
- 3. Center for Tuberculosis, University of California, San Francisco, USA
- 19. Division of Pediatric Infectious Diseases, University of California, San Francisco, San Francisco, USA
| | | |
Collapse
|
8
|
Dinh LV, Vo LNQ, Wiemers AMC, Nguyen HB, Vu HQ, Mo HTL, Nguyen LP, Nguyen NTT, Dong TTT, Tran KT, Dang TMH, Nguyen LH, Pham AT, Codlin AJ, Forse RJ. Ensuring Continuity of Tuberculosis Care during Social Distancing through Integrated Active Case Finding at COVID-19 Vaccination Events in Vietnam: A Cohort Study. Trop Med Infect Dis 2024; 9:26. [PMID: 38276637 PMCID: PMC10819868 DOI: 10.3390/tropicalmed9010026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 01/15/2024] [Accepted: 01/18/2024] [Indexed: 01/27/2024] Open
Abstract
COVID-19 significantly disrupted tuberculosis (TB) services in Vietnam. In response, the National TB Program (NTP) integrated TB screening using mobile chest X-rays into COVID-19 vaccination events. This prospective cohort study evaluated the integrated model's yield, treatment outcomes, and costs. We further fitted regressions to identify risk factors and conduct interrupted time-series analyses in the study area, Vietnam's eight economic regions, and at the national level. At 115 events, we conducted 48,758 X-ray screens and detected 174 individuals with TB. We linked 89.7% to care, while 92.9% successfully completed treatment. The mean costs per person diagnosed with TB was $547. TB risk factors included male sex (aOR = 6.44, p < 0.001), age of 45-59 years (aOR = 1.81, p = 0.006) and ≥60 years (aOR = 1.99, p = 0.002), a history of TB (aOR = 7.96, p < 0.001), prior exposure to TB (aOR = 3.90, p = 0.001), and symptomatic presentation (aOR = 2.75, p < 0.001). There was a significant decline in TB notifications during the Delta wave and significant increases immediately after lockdowns were lifted (IRR(γ1) = 5.00; 95%CI: (2.86, 8.73); p < 0.001) with a continuous upward trend thereafter (IRR(γ2) = 1.39; 95%CI: (1.22, 1.38); p < 0.001). Similar patterns were observed at the national level and in all regions but the northeast region. The NTP's swift actions and policy decisions ensured continuity of care and led to the rapid recovery of TB notifications, which may serve as blueprint for future pandemics.
Collapse
Affiliation(s)
- Luong Van Dinh
- National Lung Hospital, Ha Noi 100000, Vietnam; (L.V.D.); (H.B.N.); (H.Q.V.)
| | - Luan Nguyen Quang Vo
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
- Department of Global Health, WHO Collaboration Centre on Tuberculosis and Social Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Anja Maria Christine Wiemers
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
| | - Hoa Binh Nguyen
- National Lung Hospital, Ha Noi 100000, Vietnam; (L.V.D.); (H.B.N.); (H.Q.V.)
| | - Hoa Quynh Vu
- National Lung Hospital, Ha Noi 100000, Vietnam; (L.V.D.); (H.B.N.); (H.Q.V.)
| | - Huong Thi Lan Mo
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
| | - Lan Phuong Nguyen
- IRD VN Social Enterprise Company Limited, Ho Chi Minh City 700000, Vietnam;
| | - Nga Thi Thuy Nguyen
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
| | - Thuy Thi Thu Dong
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
| | - Khoa Tu Tran
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
| | - Thi Minh Ha Dang
- Pham Ngoc Thach Hospital, Ho Chi Minh City 700000, Vietnam; (T.M.H.D.); (L.H.N.)
| | - Lan Huu Nguyen
- Pham Ngoc Thach Hospital, Ho Chi Minh City 700000, Vietnam; (T.M.H.D.); (L.H.N.)
| | | | - Andrew James Codlin
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
- Department of Global Health, WHO Collaboration Centre on Tuberculosis and Social Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Rachel Jeanette Forse
- Friends for International Tuberculosis Relief (FIT), Ha Noi 100000, Vietnam; (A.M.C.W.); (H.T.L.M.); (N.T.T.N.); (T.T.T.D.); (K.T.T.); (A.J.C.); (R.J.F.)
- Department of Global Health, WHO Collaboration Centre on Tuberculosis and Social Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
| |
Collapse
|
9
|
Stomeo N, Ghio FE, Pallavicini P, Bonizzato S, Serini C, Perera Molligoda Arachchige AS, Carenzo L. Role of emergency teleradiology in a mass motorcycle event: the experience of the 2021 International Six Days of Enduro (ISDE). Emerg Radiol 2023; 30:725-731. [PMID: 37946090 DOI: 10.1007/s10140-023-02183-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 11/01/2023] [Indexed: 11/12/2023]
Abstract
PURPOSE Provision of healthcare support at mass gathering sporting events is of paramount importance for the success of the event. Many of such events, like motorsports, have been increasingly taking place in remote and austere environments. In these settings, the use of first-line diagnostic tools, such as point of care ultrasound and portable X-ray, could aid in definitive care on the field for patients with minor trauma while also ensuring fast access to the appropriate level of care for patients requiring hospitalization. METHODS As part of the ISDE 2021 medical response plan, a field hospital equipped with portable digital X-ray and telemedicine was established. Data on patient admission, triage, treatments, diagnostics, and outcomes were collected for analysis. RESULTS During the 6-day competition, 79 patients sought medical care at the field hospital, with traumatic injuries accounting for 77% of cases. Of these, 47 were athletes and 32 were non-athletes. The majority (91%) arrived spontaneously, while 9% were transported directly. Upon admission, 68 patients were triaged as non-urgent (code 3) and 11 as urgent (code 2). Of those admitted, 69 received treatment and were discharged at the field hospital, while 10 were transferred elsewhere. Notably, four patients had major trauma, two had isolated fractures, and one needed a CT scan after losing consciousness. Overall, 29 missions were conducted on the race field, including 13 primary transports to local hospitals and 6 to the field hospital. Primary transport was primarily due to major trauma. Among 31 patients who had radiological exams, 11 (35.5%) had traumatic injuries. Of these, 5 were treated with braces and casts and discharged without hospitalization, 3 were advised for post-event care, and 3 were hospitalized. In contrast, patients with negative X-rays received on-site treatment, with 7 able to continue competing. CONCLUSIONS In summary, the successful implementation of portable X-ray machines and teleradiology at remote and austere high-risk sporting events holds great promise for enhancing on-site medical capabilities, allowing clinicians informed decisions, avoiding unnecessary hospitalization, and allowing athletes to continue with their competition. Provided that challenges related to cost, safety, connectivity, and power supply are effectively addressed.
Collapse
Affiliation(s)
- Niccolò Stomeo
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, Italy.
| | | | - Paolo Pallavicini
- Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy
| | - Sara Bonizzato
- Critical Care Team, I-HELP, Grezzago, Italy
- Sport Medicine and Sport Cardiology Unit, MEDITEL, Saronno, Italy
| | - Carlo Serini
- Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | - Luca Carenzo
- Department of Anesthesia and Intensive Care Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| |
Collapse
|
10
|
John S, Abdulkarim S, Usman S, Rahman MT, Creswell J. Comparing tuberculosis symptom screening to chest X-ray with artificial intelligence in an active case finding campaign in Northeast Nigeria. BMC GLOBAL AND PUBLIC HEALTH 2023; 1:17. [PMID: 39681894 DOI: 10.1186/s44263-023-00017-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 08/21/2023] [Indexed: 12/18/2024]
Abstract
BACKGROUND Ultra-portable X-ray devices with artificial intelligence (AI) are increasingly used to screen for tuberculosis (TB). Few studies have documented their performance. We aimed to evaluate the performance of chest X-ray (CXR) and symptom screening for active case finding of TB among remote populations using ultra-portable X-ray and AI. METHODS We organized screening camps in rural northeast Nigeria, and all consenting individuals ≥ 15 years were screened for TB symptoms (cough, fever, night sweats, and weight loss) and received a CXR. We used a MinXray Impact system interpreted by AI (qXR V3), which is a wireless setup and can be run without electricity. We collected sputum samples from individuals with an qXR abnormality score of 0.30 or higher or if they reported any TB symptoms. Samples were tested with Xpert MTB/RIF. We documented the TB screening cascade and evaluated the performance of screening with different combinations of symptoms and CXR interpreted by AI. RESULTS We screened 5297 individuals during 66 camps: 2684 (51%) were females, and 2613 (49%) were males. Using ≥ 2 weeks of cough to define presumptive TB, 1056 people (20%) would be identified. If a cough of any duration was used, the number with presumptive TB increased to 1889 (36%) and to 3083 (58%) if any of the four symptoms were used. Overall, 769 (14.5%) had abnormality scores of 0.3 or higher, and 447 (8.4%) had a score of 0.5 or higher. We collected 1021 samples for Xpert testing and detected 85 (8%) individuals with TB. Screening for prolonged cough only identified 40% of people with TB. Any symptom detected 90.6% of people with TB, but specificity was 11.4%. Using an AI abnormality score of 0.50 identified 89.4% of people with TB with a specificity of 62.8%. CONCLUSIONS Ultra-portable CXR can be used to provide more efficient TB screening in hard-to-reach areas. Symptom screening missed large proportions of people with bacteriologically confirmed TB. Employing AI to read CXR can improve triaging when human readers are unavailable and can save expensive diagnostic testing costs.
Collapse
Affiliation(s)
- Stephen John
- Janna Health Foundation, Yola, Adamawa State, Nigeria
| | - Suraj Abdulkarim
- SUFABEL Community Development Initiative, Gombe, Gombe State, Nigeria
| | - Salisu Usman
- Yamaltu Deba, Primary Health Care Department, Gombe, Gombe State, Nigeria
| | - Md Toufiq Rahman
- Innovations & Grants, Stop TB Partnership, Global Health Campus - Chemin du Pommier 40, Le Grand-Saconnex, Geneva, 1218 , Switzerland
| | - Jacob Creswell
- Innovations & Grants, Stop TB Partnership, Global Health Campus - Chemin du Pommier 40, Le Grand-Saconnex, Geneva, 1218 , Switzerland.
| |
Collapse
|
11
|
Frija G, Salama DH, Kawooya MG, Allen B. A paradigm shift in point-of-care imaging in low-income and middle-income countries. EClinicalMedicine 2023; 62:102114. [PMID: 37560257 PMCID: PMC10406955 DOI: 10.1016/j.eclinm.2023.102114] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 07/03/2023] [Accepted: 07/06/2023] [Indexed: 08/11/2023] Open
Abstract
The concept of primary healthcare is now regarded as crucial for enhancing access to healthcare services in low-income and middle-income countries (LMICs). Technological advancements that have made many medical imaging devices smaller, lighter, portable and more affordable, and infrastructure advancements in power supply, Internet connectivity, and artificial intelligence, are all increasing the feasibility of POCI (point-of care imaging) in LMICs. Although providing imaging services at the same time as the clinic visit represents a paradigm shift in the way imaging care is typically provided in high-income countries where patients are typically directed to dedicated imaging centres, a POCI model is often the only way to provide timely access to imaging care for many patients in LIMCs. To address the growing burden of non-communicable diseases such as cancer and heart disease, bringing advanced imaging tools to the POCI will be necessary. Strategies tailored to the countries' specific needs, including training, safety and quality, will be of the utmost importance.
Collapse
Affiliation(s)
- Guy Frija
- Université Paris-Cité, 12 Rue de l’Ecole de Médecine, 75005, Paris, France
| | - Dina H. Salama
- Radiology and Medical Imaging Technology Department, Misr University for Science and Technology, Cairo, Egypt
| | - Michael G. Kawooya
- Department of Radiology, Ernest Cook Ultrasound Research and Education Institute (ECUREI), Kampala, Uganda
| | - Bibb Allen
- Department of Radiology, Grandview Medical Center, Birmingham, AL, USA
| |
Collapse
|
12
|
Charalambous S, Velen K, Rueda Z, Croda J, Herce ME, Shenoi SV, Altice FL, Muyoyeta M, Telisinghe L, Grandjean L, Keshavjee S, Andrews JR. Scaling up evidence-based approaches to tuberculosis screening in prisons. Lancet Public Health 2023; 8:e305-e310. [PMID: 36780916 DOI: 10.1016/s2468-2667(23)00002-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 12/09/2022] [Accepted: 12/20/2022] [Indexed: 02/12/2023]
Abstract
People deprived of liberty have among the highest rates of tuberculosis globally. The incidence of tuberculosis is ten times greater than the incidence of tuberculosis in the general population. In 2021, WHO updated its guidance to strongly recommend systematic screening for tuberculosis in prisons and penitentiary systems. Which case-finding strategies should be adopted, and how to effectively implement these strategies in these settings, will be crucial questions facing ministries of health and justice. In this Viewpoint, we review the evidence base for tuberculosis screening and diagnostic strategies in prisons, highlighting promising approaches and knowledge gaps. Drawing upon past experiences of implementing active case-finding and care programmes in settings with a high tuberculosis burden, we discuss challenges and opportunities for improving the tuberculosis diagnosis and treatment cascade in these settings. We argue that improved transparency in reporting of tuberculosis notifications and outcomes in prisons and renewed focus and resourcing from WHO and other stakeholders will be crucial for building the commitment and investments needed from countries to address the continued crisis of tuberculosis in prisons.
Collapse
Affiliation(s)
- Salome Charalambous
- The Aurum Institute, Johannesburg, South Africa; School of Public Health, Wits University, Johannesburg, South Africa; Division of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, CT, USA.
| | | | - Zulma Rueda
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MT, Canada; School of Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia
| | - Julio Croda
- Division of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, CT, USA; Departamento de Clínica Médica, Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil; Fiocruz Mato Grosso do Sul, Campo Grade, Brazil
| | - Michael E Herce
- Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
| | - Sheela V Shenoi
- Division of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, CT, USA; Section of Infectious Diseases, School of Medicine, Yale University, New Haven, CT, USA; University of Malaya, Centre of Excellence on Research in AIDS, Kuala Lumpur, Malaysia
| | - Frederick L Altice
- Division of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, CT, USA; Section of Infectious Diseases, School of Medicine, Yale University, New Haven, CT, USA; University of Malaya, Centre of Excellence on Research in AIDS, Kuala Lumpur, Malaysia
| | - Monde Muyoyeta
- Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
| | - Lily Telisinghe
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Louis Grandjean
- Department of Infection, Immunity and Inflammation, Institute of Child Health, University College London, UK
| | - Salmaan Keshavjee
- Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - Jason R Andrews
- Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA
| |
Collapse
|
13
|
Tchakounte Youngui B, Tchounga BK, Graham SM, Bonnet M. Tuberculosis Infection in Children and Adolescents. Pathogens 2022; 11:pathogens11121512. [PMID: 36558846 PMCID: PMC9784659 DOI: 10.3390/pathogens11121512] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 12/04/2022] [Accepted: 12/07/2022] [Indexed: 12/14/2022] Open
Abstract
The burden of tuberculosis (TB) in children and adolescents remains very significant. Several million children and adolescents are infected with TB each year worldwide following exposure to an infectious TB case and the risk of progression from TB infection to tuberculosis disease is higher in this group compared to adults. This review describes the risk factors for TB infection in children and adolescents. Following TB exposure, the risk of TB infection is determined by a combination of index case characteristics, contact features, and environmental determinants. We also present the recently recommended approaches to diagnose and treat TB infection as well as novel tests for infection. The tests for TB infection have limitations and diagnosis still relies on an indirect immunological assessment of cellular immune response to Mycobacterium tuberculosis antigens using immunodiagnostic testing. It is recommended that TB exposed children and adolescents and those living with HIV receive TB preventive treatment (TPT) to reduce the risk of progression to TB disease. Several TPT regimens of similar effectiveness and safety are now available and recommended by the World Health Organisation.
Collapse
Affiliation(s)
- Boris Tchakounte Youngui
- TransVIHMI, Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (INSERM), University of Montpellier, 34090 Montpellier, France
- Department of Public Health Evaluation and Research, Elizabeth Glaser Paediatric AIDS Foundation, Yaoundé 99322, Cameroon
- Correspondence:
| | - Boris Kevin Tchounga
- Department of Public Health Evaluation and Research, Elizabeth Glaser Paediatric AIDS Foundation, Yaoundé 99322, Cameroon
| | - Stephen M. Graham
- Department of Paediatrics and Murdoch Children’s Research Institute, Royal Children’s Hospital, University of Melbourne, Melbourne 3052, Australia
| | - Maryline Bonnet
- TransVIHMI, Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (INSERM), University of Montpellier, 34090 Montpellier, France
| |
Collapse
|
14
|
Abstract
The current diagnostic abilities for the detection of pediatric tuberculosis are suboptimal. Multiple factors contribute to the under-diagnosis of intrathoracic tuberculosis in children, namely the absence of pathognomonic features of the disease, low bacillary loads in respiratory specimens, challenges in sample collection, and inadequate access to diagnostic tools in high-burden settings. Nonetheless, the 2020s have witnessed encouraging progress in the area of novel diagnostics. Recent WHO-endorsed rapid molecular assays hold promise for use in service decentralization strategies, and new policy recommendations include stools as an alternative, child-friendly specimen for testing with the GeneXpert assay. The pipeline of promising assays in mid/late-stage development is expanding, and novel pediatric candidate biomarkers based on the host immune response are being identified for use in diagnostic and triage tests. For a new test to meet the pediatric target product profiles prioritized by the WHO, it is key that the peculiarities and needs of the hard-to-reach pediatric population are considered in the early planning phases of discovery, validation, and implementation studies.
Collapse
Affiliation(s)
| | - Pamela Nabeta
- FIND, the global alliance for diagnostics, Chemin des Mines 9, 1202 Geneva, Switzerland
| | - Morten Ruhwald
- FIND, the global alliance for diagnostics, Chemin des Mines 9, 1202 Geneva, Switzerland
| | - Rinn Song
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
| |
Collapse
|
15
|
Vaezipour N, Fritschi N, Brasier N, Bélard S, Domínguez J, Tebruegge M, Portevin D, Ritz N. Towards Accurate Point-of-Care Tests for Tuberculosis in Children. Pathogens 2022; 11:pathogens11030327. [PMID: 35335651 PMCID: PMC8949489 DOI: 10.3390/pathogens11030327] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 03/02/2022] [Accepted: 03/03/2022] [Indexed: 12/20/2022] Open
Abstract
In childhood tuberculosis (TB), with an estimated 69% of missed cases in children under 5 years of age, the case detection gap is larger than in other age groups, mainly due to its paucibacillary nature and children’s difficulties in delivering sputum specimens. Accurate and accessible point-of-care tests (POCTs) are needed to detect TB disease in children and, in turn, reduce TB-related morbidity and mortality in this vulnerable population. In recent years, several POCTs for TB have been developed. These include new tools to improve the detection of TB in respiratory and gastric samples, such as molecular detection of Mycobacterium tuberculosis using loop-mediated isothermal amplification (LAMP) and portable polymerase chain reaction (PCR)-based GeneXpert. In addition, the urine-based detection of lipoarabinomannan (LAM), as well as imaging modalities through point-of-care ultrasonography (POCUS), are currently the POCTs in use. Further to this, artificial intelligence-based interpretation of ultrasound imaging and radiography is now integrated into computer-aided detection products. In the future, portable radiography may become more widely available, and robotics-supported ultrasound imaging is currently being trialed. Finally, novel blood-based tests evaluating the immune response using “omic-“techniques are underway. This approach, including transcriptomics, metabolomic, proteomics, lipidomics and genomics, is still distant from being translated into POCT formats, but the digital development may rapidly enhance innovation in this field. Despite these significant advances, TB-POCT development and implementation remains challenged by the lack of standard ways to access non-sputum-based samples, the need to differentiate TB infection from disease and to gain acceptance for novel testing strategies specific to the conditions and settings of use.
Collapse
Affiliation(s)
- Nina Vaezipour
- Mycobacterial and Migrant Health Research Group, University Children’s Hospital Basel, Department for Clinical Research, University of Basel, 4056 Basel, Switzerland; (N.V.); (N.F.)
- Infectious Disease and Vaccinology Unit, University Children’s Hospital Basel, University of Basel, 4056 Basel, Switzerland
| | - Nora Fritschi
- Mycobacterial and Migrant Health Research Group, University Children’s Hospital Basel, Department for Clinical Research, University of Basel, 4056 Basel, Switzerland; (N.V.); (N.F.)
| | - Noé Brasier
- Department of Health Sciences and Technology, Institute for Translational Medicine, ETH Zurich, 8093 Zurich, Switzerland;
- Department of Digitalization & ICT, University Hospital Basel, 4031 Basel, Switzerland
| | - Sabine Bélard
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany;
- Institute of Tropical Medicine and International Health, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany
| | - José Domínguez
- Institute for Health Science Research Germans Trias i Pujol. CIBER Enfermedades Respiratorias, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain;
| | - Marc Tebruegge
- Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London WCN1 1EH, UK;
- Department of Pediatrics, The Royal Children’s Hospital Melbourne, The University of Melbourne, Parkville, VIC 3052, Australia
| | - Damien Portevin
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland;
- University of Basel, 4001 Basel, Switzerland
| | - Nicole Ritz
- Mycobacterial and Migrant Health Research Group, University Children’s Hospital Basel, Department for Clinical Research, University of Basel, 4056 Basel, Switzerland; (N.V.); (N.F.)
- Department of Pediatrics, The Royal Children’s Hospital Melbourne, The University of Melbourne, Parkville, VIC 3052, Australia
- Department of Paediatrics and Paediatric Infectious Diseases, Children’s Hospital, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland
- Correspondence: ; Tel.: +41-61-704-1212
| |
Collapse
|